Merck / MSD
LIPFENDRA is a U.S.-approved oral PCSK9 inhibitor. Its label confirms sodium caprate and approximately 1% oral bioavailability.
Corporate information
- Company entity
- Merck & Co., Inc.（MSD; distinct from Germany-based Merck KGaA）
- Headquarters / principal office
- Rahway, New Jersey, USACorporate website explicitly identifies headquarters; location follows the retrieved disclosure. ↗
- Founded
- 1891 ↗
- Ownership / capital status
- Publicly tradedPublicly traded ↗
- Official corporate reference
- https://www.merck.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public evidence snapshot
enlicitide (MK-0616) is a PCSK9 macrocyclic peptide; its 2026 U.S. label supports approved status.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.